1. Home
  2. MPLT vs TRS Comparison

MPLT vs TRS Comparison

Compare MPLT & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$11.75

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo TriMas Corporation

TRS

TriMas Corporation

HOLD

Current Price

$38.94

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
TRS
Founded
2018
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
MPLT
TRS
Price
$11.75
$38.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$32.67
$41.50
AVG Volume (30 Days)
1.3M
419.9K
Earning Date
05-28-2026
04-30-2026
Dividend Yield
N/A
0.44%
EPS Growth
82.39
400.00
EPS
N/A
21.96
Revenue
N/A
$645,720,000.00
Revenue This Year
N/A
$5.42
Revenue Next Year
N/A
$4.27
P/E Ratio
N/A
$1.76
Revenue Growth
N/A
N/A
52 Week Low
$9.10
$30.43
52 Week High
$40.43
$45.43

Technical Indicators

Market Signals
Indicator
MPLT
TRS
Relative Strength Index (RSI) 28.18 40.24
Support Level $9.10 $35.69
Resistance Level $20.73 $39.33
Average True Range (ATR) 1.49 1.53
MACD -0.16 -0.09
Stochastic Oscillator 35.72 51.65

Price Performance

Historical Comparison
MPLT
TRS

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

Share on Social Networks: